Archive · 6 Oct 2026
Zydus and MSN Launch First Generic Riociguat in US
Zydus Lifesciences and MSN Laboratories have launched a generic version of a medicine called Riociguat in the United States.
A generic medicine is another version of an existing medicine.
This one is the first generic version of Adempas in the US, according to the filing.
It comes in five different strengths.
The US Food and Drug Administration approved it as a generic equivalent of Adempas tablets.
The medicine is intended for adults with certain kinds of high blood pressure in the lungs.
Zydus said the launch is an important step for its US business.
MSN said it reflects its research and manufacturing capabilities.
Bayer reported that Adempas had global sales of about USD 850 million in 2025.
Zydus Lifesciences and MSN Laboratories launched the first generic version of Adempas in the US.
The tablets are available in five strengths, from 0.5 mg to 2.5 mg.
MSN Laboratories developed and manufactured the product, which received USFDA approval as a generic equivalent.
Riociguat is indicated for adults with certain forms of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.
Bayer's 2025 annual report put global Adempas sales at approximately USD 850 million.
- Who
- Zydus Lifesciences Limited and MSN Laboratories Private Limited.
- What
- They launched the first US generic version of Adempas (Riociguat tablets), in five strengths.
- When
- Published October 6, 2026.
- Where
- The United States.
- Why
- The generic is indicated for adults with certain forms of chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
- Product
- Generic Riociguat tablets, equivalent to Adempas
- Strengths
- 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg
- Developer and manufacturer
- MSN Laboratories
- Regulatory approval
- Approved by the US Food and Drug Administration as a generic equivalent of Adempas tablets
- Indications
- Certain cases of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) in adults
- Adempas sales
- Approximately USD 850 million globally in 2025, according to Bayer's Annual Report 2025 cited in the filing
- Publication date
- October 6, 2026